SCHEDULE: FMR LLC Boosts Stake in X4 Pharmaceuticals to 14.8%
Beneficial Ownership Report
FMR LLC and its affiliates, including Abigail P. Johnson, reported a 14.8% beneficial ownership stake in X4 Pharmaceuticals Inc. common stock as of October 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 8,499,100 shares of X4 PHARMACEUTICALS INC common stock.
- This ownership represents 14.8% of the total outstanding common stock of X4 PHARMACEUTICALS INC.
- FMR LLC holds sole voting power and sole dispositive power over all 8,499,100 shares.
- Abigail P. Johnson holds sole dispositive power over 8,499,100 shares, but no sole or shared voting power.
- Fidelity Small Cap Growth Fund, a subsidiary of FMR LLC, holds 3,386,200 shares, representing 5.9% of the total outstanding common stock.
- The shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing indicates a significant institutional stake by a major asset manager, which is generally viewed as a positive sign of confidence in the company, although it provides no operational or financial performance details.
Positives
- Significant institutional investment by FMR LLC, a major asset manager, indicates confidence in X4 Pharmaceuticals Inc.
- The substantial 14.8% stake could attract further investor interest and potentially stabilize the stock price.
Risks
- None directly mentioned regarding X4 Pharmaceuticals Inc.'s operations or future challenges in this ownership disclosure.
Future Outlook
This filing is an ownership disclosure and does not contain forward-looking statements or guidance regarding X4 Pharmaceuticals Inc.'s future performance or operations.
Industry Context
Institutional investors like FMR LLC frequently take significant stakes in publicly traded companies, including those in the biotechnology and pharmaceutical sectors, as part of their diversified investment strategies. A substantial stake by a prominent asset manager can signal perceived value or growth potential within the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Governance Disclosure | Members of the Johnson family, including Abigail P. Johnson, are the predominant owners of Series B voting common shares of FMR LLC (49% voting power) and have a shareholders' voting agreement to vote in accordance with the majority, potentially forming a controlling group with respect to FMR LLC under the Investment Company Act of 1940. | This clarifies the internal control structure of FMR LLC, the reporting entity, rather than X4 Pharmaceuticals Inc. It ensures transparency regarding the ultimate control of the reported shares. |
Stakeholder Impact
- Shareholders: May view the significant institutional ownership as a positive indicator of confidence and potential stability for the stock.
- Investors: Provides transparency regarding a major institutional investor's position in X4 Pharmaceuticals Inc.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC, incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson, incorporated by reference. |
| 2025-10-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-11-06 | Date of filing of this Schedule 13G. |
Keywords
X4 Pharmaceuticals, FMR LLC, Abigail P. Johnson, Institutional Ownership, Common Stock, Beneficial Ownership, Schedule 13G, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.